Sponsors

Micafungin added to fungal susceptibility card

bioMérieux has created a new fungal susceptibility card for susceptibility testing of Candida species and Cryptococcus neoformans. The VITEK 2 ASTYS07 card includes a sixth antifungal agent, micafungin, providing a valuable enhancement to antifungal susceptibility testing.

Yeast infections have become a major cause of morbidity and mortality in at-risk patient populations. Early diagnosis and prompt treatment are key to achieving successful outcomes in these infections, and bioMérieux’s VITEK 2 instrument offers automated, standardised and rapid yeast susceptibility
testing.

The VITEK 2 AST-YS07 fungal susceptibility card, which replaces VITEK 2 AST-YS06, complements the current antifungals – amphotericin B, caspofungin, fluconazole, flucytosine and voriconazole – with micafungin, an echinocandin active against Candida species, extending the capabilities of the
VITEK 2 and helping to ensure that the correct treatment is initiated swiftly.
www.biomerieux.com

Latest Issues

IHC technical issues masterclass

UK NEQAS CPT, The Haylofts, Newcastle
13 August, 2025

37th European Congress of Pathology

ACV, Vienna, Austria
6 -10 September, 2025

IBMS Congress

The International Convention Centre (ICC), Birmingham
22-25 September, 2025